External broker reports(aggregated public sources), HDFC Securities

HDFC Securities

HDFC securities is the best online trading platform for stocks, IPOs, mutual fund in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

HDFC securities is the best online trading platform for stocks, IPOs, mutual fund in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

Metropolis Healthcare Limited / Equity Bottom-Up

Metropolis Healthcare Limited (METROHL IN)

<ul><li>Metropolis signed a definite agreement to acquire a 100% stake in Core Diagnostics</li><li>This acquisition will strengthen its advanced cancer testing capabilities and its footprint in the North and East regions</li><li>The total consideration of INR 2.46 bn (2.2x EV/sales for FY24, 2x EV/sales for FY25, and 13.9/14x EV/EBITDA for FY25/26E) will be discharged by (1) cash of INR 1.36 bn and (2) a preferential issue and allotment of equity shares (share swap)</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Metropolis signed a definite agreement to acquire a 100% stake in Core DiagnosticsThis acquisition will strengthen its advanced cancer testing capabilities and its footprint in the North and East regionsThe total consideration of INR 2.46 bn (2.2x EV/sales for FY24, 2x EV/sales for FY25, and 13.9/14x EV/EBITDA for FY25/26E) will be discharged by (1) cash of INR 1.36 bn and (2) a preferential issue and allotment of equity shares (share swap)Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Metropolis Healthcare: Core Diagnostic M&A to Strengthen Speciality Portfolio.